Key result
Adjuvant radiation therapy achieves 33-month disease-free survival without significant late toxicity in a single patient.
Why the study?
Cardiac intimal sarcomas are rare, aggressive primary cardiac malignancies with limited data guiding adjuvant treatment.
Does adjuvant radiation therapy provide long-term disease control in a patient with cardiac intimal sarcoma?
Case Report (n=1)
No
Does adjuvant radiation therapy provide long-term disease control in a patient with cardiac intimal sarcoma?
* *Idea:* Suggests adjuvant radiation may be feasible for cardiac intimal sarcoma.
Cardiac intimal sarcomas (CIS) are rare, aggressive primary cardiac malignancies with limited data guiding adjuvant treatment. We report a case of a 40-year-old woman with bi-atrial CIS who underwent bi-atrial resection and mitral valve replacement, with pathology confirming an MDM2-amplified intimal sarcoma and positive margins (R1). She received four cycles of adjuvant chemotherapy followed by adjuvant radiation therapy (RT) delivered using volumetric modulated arc therapy (VMAT), planned with four-dimensional computed tomography to account for respiratory motion, to a total dose of 60 Gy with a 6-Gy sequential boost. Treatment was well tolerated, with only grade 1-2 acute toxicities that resolved by completion of therapy. At 33 months following completion of RT and 41 months from diagnosis, the patient remains alive and disease-free without evidence of recurrence or significant late toxicity. This case supports the feasibility of incorporating adjuvant RT into a multimodal treatment approach for CIS and suggests that advanced radiation planning techniques may allow safe delivery of curative-intent doses to the heart, although further studies are needed to define its role in this rare malignancy.
No takes yet. Share an insight, caveat, or question.
Rosa et al. (2026) conducted a case report in Cardiac intimal sarcoma (n=1). Adjuvant radiation therapy (VMAT) was evaluated on Disease-free survival and late toxicity. Adjuvant radiation therapy to a total dose of 66 Gy resulted in the patient remaining alive and disease-free 33 months post-treatment without significant late toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: